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Abstract
Adult human cardiac mesenchymal-like stromal cells (CStC) represent a relatively accessible cell type useful for therapy. In
this light, their conversion into cardiovascular precursors represents a potential successful strategy for cardiac repair. The
aim of the present work was to reprogram CStC into functionally competent cardiovascular precursors using epigenetically
active small molecules. CStC were exposed to low serum (5% FBS) in the presence of 5 mM all-trans Retinoic Acid (ATRA),
5 mM Phenyl Butyrate (PB), and 200 mM diethylenetriamine/nitric oxide (DETA/NO), to create a novel epigenetically active
cocktail (EpiC). Upon treatment the expression of markers typical of cardiac resident stem cells such as c-Kit and MDR-1 were
up-regulated, together with the expression of a number of cardiovascular-associated genes including KDR, GATA6, Nkx2.5,
GATA4, HCN4, NaV1.5, and a-MHC. In addition, profiling analysis revealed that a significant number of microRNA involved in
cardiomyocyte biology and cell differentiation/proliferation, including miR 133a, 210 and 34a, were up-regulated.
Remarkably, almost 45% of EpiC-treated cells exhibited a TTX-sensitive sodium current and, to a lower extent in a few cells,
also the pacemaker If current. Mechanistically, the exposure to EpiC treatment introduced global histone modifications,
characterized by increased levels of H3K4Me3 and H4K16Ac, as well as reduced H4K20Me3 and H3s10P, a pattern
compatible with reduced proliferation and chromatin relaxation. Consistently, ChIP experiments performed with H3K4me3
or H3s10P histone modifications revealed the presence of a specific EpiC-dependent pattern in c-Kit, MDR-1, and Nkx2.5
promoter regions, possibly contributing to their modified expression. Taken together, these data indicate that CStC may be
epigenetically reprogrammed to acquire molecular and biological properties associated with competent cardiovascular
precursors.
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Introduction
Cellular cardiomyoplasty is a promising therapy to reconstitute
injured hearts. Cell based interventions aimed at structurally
regenerating the heart imply that transplanted cells graft in the
host tissue and adopt the phenotype of resident cardiomyocytes,
endothelial cells and smooth muscle cells. In this light, cells
possessing pluripotency, such as embryonic stem (ES) cells and the
so-called induced-pluripotent stem cells (iPS) [1] may be consid-
ered a good candidate. Yet, although several attempts have been
made to simplify iPS cell generation methods avoiding the
undesired effect of neoplastic transformation [2], their use still
raises safety concerns. Consequently, much effort has been put
into promoting cardiovascular differentiation of adult cells.
Intriguingly, a recent work has shown the possibility of directly
converting neonatal or embryonic mouse fibroblasts into cardio-
myocytes by a transcription-factor based reprogramming strategy
[3]. In spite of its potential practical relevance, the efficiency of this
procedure is low and genetic manipulation of target cells is still
required. In this context, chemical strategies based on the use of
small active molecules represent an easier, more effective and safer
alternative to genetic methods [4]. Further, achieving terminal
differentiation of adult somatic or stem cells into cardiomyocytes
may not be the right therapeutic approach, as multiple cell types
(i.e. cardiomyocytes, vascular cells, and fibroblasts) should be
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reprogramming of adult cardiac cells into progenitors, which are
less de-differentiated than iPS cells and exhibit lineage commit-
ment restricted to the cell types of interest, may represent a
successful strategy.
In addition to adult cardiac stem cells, a different category of
heart cells, namely cardiac mesenchymal stromal cells (CStC)
deriving from the cardiac parenchyma, have been recently isolated
and characterized by our group [5]. CStC are c-Kit negative,
reveal positivity for both pericytes (i.e. CD146) and fibroblast
markers (i.e. vimentin and human fibroblast surface antigen) and
share similarities with syngeneic bone marrow mesenchymal
stromal cells (BMStC), showing comparable morphology and
expression of mesenchymal-associated antigens (i.e. CD105,
CD73, CD29, and CD44). Despite their similarities, significant
differences between CStC and BMStC emerged. In fact, CStC
may be identified by the expression of a specific microRNA
signature and exhibit a residual plasticity toward the cardiovas-
cular lineage, possessing the ability to contribute new adult-like
cardiomyocytes after heart ischemia with higher efficiency than
BMStC [5]. Of note, CStC are easily obtained from small
biopsyspecimens and may be efficiently grown in vitro.
A large number of evidences indicate that biological response
modifiers, including epigenetically active small molecules, such as
histone deacetylase inhibitors (HDACi), may facilitate the
redirection of adult cellular functions toward stemness [4]. So
far, however, no reportsdescribed the in vitro enhancement of adult
cardiac precursors via a defined cocktail of drugs.
In this report, we describe the properties of CStC chemically
converted into functional cardiovascular precursors by means of
nutrients deprivation in the presence of retinoids, phenyl butyrate
and nitric oxide drugs. Remarkably, these drugs have been used in
the past to stimulate in vitro cardiomyocyte production in different
experimental contexts [6,7,8], but they were never combined
together on cells isolated from human adult heart. These
compounds have different mechanisms of action including nuclear
receptor activation (retinoic acid) [9] and inhibition of histone
deacetylases (phenyl butyrate). Further, nitric oxide donors such as
DETA/NO, have been shown to play a role in the prevention of
apoptosis, microRNA up-regulation [10] and cardiac commitment
[11]. Therefore it is possible that these drugs may synergize in
determining the generation of functionally competent cardiovas-
cular precursor-like cells.
Materials and Methods
Ethics Statement
Cardiac stromal cells were obtained from right auricle samples
of donor patients undergoing valve substitution or by-pass surgery
after signed informed consent and approval by the Centro
Cardiologico Monzino (Milano, Italy) Ethical Committee. Inves-
tigations were conducted according to the principles expressed in
the Declaration of Helsinki. Data were analyzed anonymously.
CStC Isolation and Culture
CStC were isolated from right auricles and cultured in growth
medium (GM) as previously described [5]. CStC at passages 4–8
were incubated for 7 days with an Epigenetic cocktail (EpiC),
composed by Iscove’s Modified Dulbecco’s Medium (IMDM), 5%
Foetal Bovine Serum (FBS), 10.000 U/ml Penicillin/Streptomicin,
10 mg/ml L-Glutamine, 5 mM All trans Retinoic Acid (ATRA),
5 mM Phenyl Butyrate (PB), and 200 mM diethylenetriamine/
nitric oxide (DETA/NO), all purchased from Sigma Aldrich. The
EpiC medium was changed every 48 hrs.
Western Blot Analysis
CStC in control and EpiC media were lysed with Laemmli
buffer in presence of protease and phosphatase inhibitors (Roche
Diagnostic). Proteins were resolved by SDS–PAGE, transferred
onto nitrocellulose membranes (Bio-Rad Laboratories), and
incubated overnight at 4uC with primary antibodies listed in
Supplementary Table S1. Subsequently, the blots were incubated
with the appropriate anti-rabbit, anti-mouse, or anti-goat horse-
radish peroxidase-conjugated secondary antibody (Amersham-GE
Healthcare). ECL or, when appropriate, ECL plus (Amersham-
GE Healthcare) were used for chemiluminescence detection. Each
filter was also probed with anti-b-actin, anti-b-tubulin, anti-H3, or
anti-H4, to verify equal protein loading. Densitometric analyses
were performed by NIH ImageJ software, version 1.4.3.67.
Figure 1. Effect of EpiC treatment on CStC growth, viability and
senescence. (A) Growth curve of CStC cultured in GM or EpiC for 5, 7,
and 14 days (n=7). (B) Quantification of free nucleosomes, used as
markers of apoptosis, in CStC exposed to GM or EpiC for7 days.
Ctrl+=positive control supplied by the manufacturer. (C) Staining for
senescence-related acidic b-galactosidase (b-gal ) performed on CStC
grown either in GM or in EpiC medium. Positivity for b-gal is indicated
b yt h ep r e s e n c eo fad a r kg r e ys t a i nw i t h i nt h ec y t o p l a s m .
Ctrl+=primary bone marrow mesenchymal stromal cells at passage
10 (replicative senescence). Bar Graph shows average percentage of b-
gal positive cells (n=4). Original magnification: 206.
doi:10.1371/journal.pone.0051694.g001
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Reaction Analysis
Total RNA was extracted from cells using the TRIzol reagent
and 500 ng of RNA were reverse-transcribed using Superscript III
reverse transcriptase (Invitrogen). cDNA was amplified by SYBR-
GREEN quantitative PCR in an iQ5 Cycler (Bio-Rad Laborato-
ries). Primer sequences are reported in Supplementary Table S2.
Relative expression was estimated using the DeltaCt (DCt)
method. DDCt were calculated using average DCt for each gene
expression in GM. Fold changes in gene expression were estimated
as 2
(2DDCt). DCt=25 was arbitrarily assigned to non-expressed
genes.
microRNA Profiling Analysis
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen), according to the manufacturer’s instructions. The
concentration and purity of RNA were determined using a
NanoDrop 1000 spectrophotometer (Thermo Scientific), and only
highly pure preparations (ratio of 260/280.1.8 and 260/
230.1.8) were used. The integrity of total RNA was assessed
using an Experion electrophoresis system and the RNA high sense
Analysis Kit (Bio-Rad Laboratories) and only highly quality RNA
(RQI .9.5/10) was subjected to subsequent analysis. Compara-
tive microRNA expression profiling was carried out using
TaqMan Low Density Arrays Human MicroRNA A+B Cards
Set v3.0 (Applied Biosystems). All procedures were performed
according to the manufacturer’s instructions, on a 7900HT Real-
Time PCR System (Applied Biosystems).
Quality control and low level analysis of TaqMan Arrays were
performed using the software ABI Prism SDS v2.4. Optimal
baseline and Ct (threshold cycle) were determined automatically
by the software algorithm. All Ct values reported as greater than
35 or as not detected were changed to 35 and considered negative
calls. Raw expression intensities of target microRNAs were
normalized for differences in the amount of total RNA added to
each reaction using the mean expression value of all expressed
microRNAs in a given sample, following the method described by
Mestdagh and co-workers [12]. Relative quantitation of micro-
RNA expression was performed using the comparative Ct method
(DCt). DCt values were defined as the difference between the Ct of
any microRNA in the calibrator sample (the sample with the
highest expression, i.e. lowest Ct value) and the Ct of the same
microRNA in experimental sample. The Ct values were trans-
formed to raw quantities using the formula g
DCt, where
amplification efficiency (g) was set arbitrarily to 2 (100%). The
normalized relative expression quantity of each microRNA was
calculated by dividing its raw quantity by the normalization factor.
MicroRNAs that had missing values in greater than 50% of the
samples (i.e. that were not present at least in all cells on one
treatment) were deemed as uninformative and removed from the
dataset.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed and DNA fragments analyzed by
quantitative real-time PCR (qPCR) as previously described [13].
Briefly, standard curves were generated by serially diluting the
input DNA (5-log dilutions in triplicate) and qPCR was done on
an ABI Prism 7500 PCR instrument (Applied Biosystems), using a
SYBR Master mix (Applied Biosystems) and evaluating the
dissociation curves. The qPCR analyses were performed in
duplicate and the data obtained were normalized to the
corresponding DNA input. Data are represented as relative
enrichment of specific histone modifications in EpiC-treated cells
compared to growth medium (GM). Primers for human promoters
Figure 2. Effect of EpiC treatment on stem cell marker expression. Western blotting analysis of (A) adult cardiac stem cell marker c-Kit and
MDR-1 (n=4) and (B) Notch, Jagged-1, Numb and nucleostemin (NS) in CStC, grown either in GM or in EpiC (n=6). Densitometry is shown in the bar
graphs at the bottom of each panel (**P#0.01, *P#0.05 vs GM). FL=full length protein; TM=Transmembrane domain.
doi:10.1371/journal.pone.0051694.g002
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GAGCAGAAACAATTAGCGAAACC (2560 bp); c-Kit rev:
GGAAATTGAGCCCCGACATT (2468 bp); Nkx2.5 fw:
TGACTCTGCATGCCTCTGGTA (2198 bp); Nkx2.5 rev:
TGCAGCCTGCGTTTGCT (2138 bp); MDR-1 fw:
TTCCTCCACCCAAACTTATCCTT (-93 bp); MDR-1 rev:
CCCAGTACCAGAGGAGGAGCTA (22 bp); hGNL3 fw:
GAGTTTGTGTCGAACCGTCAAG (2563 bp); hGNL3 rev:
TCCCTCAGTCCCCAATACCA (2457 bp).
Electrophysiology
Patch-clamp analysis was performed on CStC perfused with a
normal Tyrode solution containing (mM): 140 NaCl, 5.4 KCl, 1.8
CaCl2, 5.5 D-glucose, 5 Hepes-NaOH; pH 7.4. Patch pipettes
were filled with a solution containing (mM): 130 K-Aspartate,
10 NaCl, 5 EGTA-KOH, 2 CaCl2, 2 MgCl2, 2 ATP (Na-salt), 5
creatine phosphate, 0.1 GTP (Na-salt), 10 Hepes-KOH; pH 7.2
and had resistances of 2 to 4 MOhm. Experiments were carried
out at room temperature.
The fast Na+ current (INa) was activated by 50 ms steps to the
range 280/+30 mV from a holding potential of 290 mV. Peak I-
V relations were constructed by plotting the normalized peak
Figure 3. Effect of EpiC treatment of cardiovascular marker expression. Immunoblots showing expression analyses of (A) vascular markers:
VEGFR-2, GATA6, and a-smooth muscle actin (a-SMA); (B) early cardiomyogenic markers: Mef2c, GATA4, and Nkx2.5; (C) late cardiomyogenic markers
a-MHC, a-Sarc, and Tn-TC in EpiC-treated CStC compared to cells in GM. Bar graphs represent average results, normalized to b-actin, of western blot
densitometric analyses (*P#0.05, **P,0.01, and ***P#0.005, vs GM). The data represent the mean 6 SD of 4 independent experiments performed in
duplicate.
doi:10.1371/journal.pone.0051694.g003
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rectifying K+ current (IK1) was investigated by applying 4 s
voltage-ramps from 2100 to 25 mV in Tyrode solution and after
addition of Ba
2+ (2 mM BaCl2), a known blocker of IK1. To record
the If current, 1 mM BaCl2 and 2 mM MnCl2 were added to
normal Tyrode in order to block contaminating currents. If was
activated by a standard activation protocol [14]. Hyperpolarizing
test steps to the range 235/2125 mV were applied from a
holding potential of 230 mV, followed by a fully activating step at
2125 mV. Each test step was long enough to reach steady-state
current activation. Normalized tail currents measured at
2125 mV were used to plot activation curves, which were fitted
to the Boltzmann distribution function: y=(1/(1+exp((V-V1/2)/s),
where V is voltage, y fractional activation, V1/2 the half-activation
voltage, and s the inverse slope factor. Measured values are
reported as mean 6 SEM.
Statistics
Statistical analysis of real-time PCR, Western Blot, and HDAC
Class I activity data was performed using Student’s t-test. A
P,0.05 was considered significant.
Statistical analysis of the TaqMan Arrays was performed using
the MultiExperiment Viewer (MeV) software v4.8.1 [15]. micro-
RNAs with a fold change between the two treatment groups less
than 62 were filtered out. Normalized expression values were log2
transformed and differentially expressed microRNAs were iden-
tified using a paired t-test computing p-values based on all
available permutations with a confidence level of 95% and limiting
the false discovery rate (FDR) proportion to ,0.15. Differences in
microRNA expression were considered statistically significant if
their P-value was ,0.05. Unsupervised hierarchical cluster
analysis was performed to assess whether differential profile
discriminates the EpiC from the control treated cells. The
similarity of microRNA expression among arrays and probes
was assessed by calculating the Pearson’s correlation (uncentered)
coefficient. Normalized log2 transformed expression values were
mean centered and clustered by correlation average linkage, using
leaf order optimization.
Supplementary Methods
An additional Methods section is available as Supporting
Information Document S1.
Results
Epigenetic Cocktail (EpiC) Design
Human cardiac stromal cells (CStC) cultured in standard
medium for mesenchymal cells (GM) are positive for the
mesenchymal markers CD105, CD29 and CD73, but negative
for adult cardiac stem cell markers Sca-1, c-Kit and VEGFR2
(Figure S1A).
The level of nutrients (i.e. foetal serum) and the presence of
selected drugs can modify cell phenotype and fate inducing
functional reprogramming [4]. In light of this, after expansion in a
medium routinely used for mesenchymal cell culture (growth
medium, GM), CStC were exposed for 7 days to a medium with
reduced level of foetal bovine serum (5% FBS) either in the
presence or in the absence of 5 mM all-trans retinoic acid (ATRA),
5 mM phenyl butyrate (PB) and 200 mM diethylenetriamine/nitric
oxide (DETA/NO), alone or in combination. In all these
conditions, the expression of markers associated with resident
cardiac stem cells (c-Kit, VEGFR2, and MDR-1) [16,17] has been
evaluated. Our findings indicated that, although serum depriva-
tion alone or a single drug exhibited the ability to up-regulate the
expression of one or more markers, only the complete formulation,
defining a novel ‘‘epigenetic cocktail’’ (EpiC), induced the
coincident expression of c-Kit, VEGFR2, and MDR-1 in CStC
(Figure S1B). Notably, EpiC treatment, while stopping cell
proliferation, did neither induce apoptosis or senescence
(Figure 1), nor stimulate CStC to differentiate into other
mesodermal cells such as adipocytes or osteoblasts (Figure S1C),
nor modulated the expression of Sca-1 and typical mesenchymal
markers such as CD105 (not shown).
Effects of EpiC Treatment on Stem and Cardiovascular
Precursor Markers
EpiC treatment of CStC strongly up-regulated markers
associated to cardiac resident adult stem cell such as c-Kit and
MDR-1 (Figure 2A and Figure S2A). In this condition, we were
able to demonstrate that the MDR-1 transporter was functionally
active as indicated by the rhodamine extrusion assay (Figure S2B).
Table 1. Differentially expressed microRNAs.
microRNA GM EpiC FC P-value FDR
miR-133a 0.0760.07 0.8660.43 11.88 0.0488 0.13
miR-34a 0.2660.10 1.2360.13 4.78 0.0266 0.12
miR-664 0.3060.09 1.4460.34 4.75 0.0035 0.06
miR-34a# 0.3160.13 1.3360.61 4.27 0.0209 0.10
miR-210 0.2560.10 1.0460.29 4.19 0.0266 0.11
miR-200b 0.3360.16 1.3460.63 4.06 0.0492 0.13
miR-146b-5p 0.2960.04 1.0060.31 3.42 0.0442 0.14
miR-145 0.3160.23 0.9560.47 3.09 0.0346 0.13
miR-362-3p 0.4860.10 1.5060.35 3.09 0.0002 0.02
miR-1300 0.3160.18 0.9360.38 3.02 0.0126 0.09
miR-204 0.3860.03 1.1460.16 2.99 0.0124 0.09
miR-452 0.4260.13 1.2060.17 2.87 0.0113 0.10
miR-30a-5p 0.4360.05 1.1360.23 2.63 0.0056 0.08
miR-21 0.4060.19 1.0260.29 2.52 0.0478 0.13
miR-140-5p 0.5260.07 1.2860.05 2.46 0.0114 0.09
miR-30e-3p 0.5560.12 1.3160.27 2.37 0.0181 0.10
miR-26b# 0.4960.07 1.0960.18 2.22 0.0423 0.14
miR-22# 0.6460.25 1.4060.31 2.19 0.0162 0.09
miR-30a-3p 0.5660.19 1.1460.25 2.03 0.0140 0.09
miR-574-3p 0.6060.11 1.2160.16 2.02 0.0445 0.13
miR-663B 1.3260.34 0.6360.02 22.08 0.0397 0.14
miR-20b 1.2860.34 0.5860.20 22.21 0.0455 0.13
miR-708 1.0760.51 0.4660.19 22.34 0.0020 0.04
miR-92a 1.5860.27 0.6860.07 22.34 0.0303 0.12
miR-376a 1.1560.70 0.4360.23 22.71 0.0093 0.09
miR-942 1.3860.92 0.3660.22 23.82 0.0009 0.04
miR-18a 1.1660.79 0.3060.19 23.91 0.0072 0.08
miR-223 1.3560.38 0.3260.12 24.17 0.0017 0.05
miR-29b-1# 1.5160.82 0.3560.09 24.38 0.0282 0.11
miR-155 1.8360.43 0.4060.15 24.54 0.0206 0.10
miR-15b# 1.5360.75 0.1560.04 210.42 0.0429 0.14
microRNA normalized relative expression levels in GM and EpiC-treated cells are
expressed as mean 6 SD. FC=fold change. FDR=false discovery rate.
doi:10.1371/journal.pone.0051694.t001
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Jagged-1 and Numb [18,19] were also increased (Figure 2B), while
the expression of the pluripotency factors Oct4 and Nanog
remained negative (not shown). In this condition, EpiC-treated
cells were growth arrested (Figure 1A) and nucleostemin (NS), a
nucleolar protein present in proliferating stem cells [20], was
down-regulated (Figure 2B). Of note, untreated CStC expressed
detectable level of GATA6, a-smooth muscle actin and GATA4,
whose expression is associated with processes ongoing during
vascular and cardiac commitment [21,22,23]. Interestingly, EpiC
treatment increased the expression of markers for both vascular
(VEGFR2, GATA6, and a-smooth muscle actin) and cardiomyo-
genic (GATA4 and Nkx2.5) precursors, while leaving Mef2C
expression unaltered (Figure 3A and 3B). However, in spite of the
evidence that more mature cardiomyogenic markers could be
detected in EpiC-treated CStC, such as a-sarcomeric actin (a -
Sarc) and a-myosin heavy chain (a -MHC), neither sarcomere
Figure 4. Hierarchical clustering of differentially expressed microRNAs in GM and EpiC-treated CStC. Unsupervised cluster analysis was
performed using the 31 microRNAs that showed a significant modulation induced by the EpiC treatment. The dendrogram above shows that the
differential expression profile completely discriminates the two treatment groups. The dendrogram on the left shows two distinct clusters of
microRNAs up- and down-regulated by EpiC treatment in CStC (respectively at the top and the bottom of the heatmap). The mean centered value of
normalized log2 transformed relative expression level of each microRNA is represented with a green, black, and red color scale (green indicates below
mean; black, equal to mean; and red, above mean).
doi:10.1371/journal.pone.0051694.g004
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observed (Figure 3C).
Effects of EpiC Treatment on CStC MicroRNA Expression
Profile
microRNAs (miR) are 22–23 nucleotide-long, single-stranded
ribonucleic molecules usually involved in transcriptional repression
and gene silencing [24]. As miR are known to have important
roles in cell reprogramming [25] and cell differentiation [26], their
expression profile was evaluated in CStC after 7 days of exposure
to EpiC. Two hundred and sixty-one microRNAs passed the
quality assurance and filtering criteria: their normalized relative
expression levels and fold-differences between EpiC and GM-
treated cells, along with the raw P-values, are reported in
Supplementary Table S3. Results of the differential analysis
(Table 1) showed that 31 microRNAs were significantly modulated
by EpiC treatment. In particular, 20 microRNAs were up-
regulated .2-fold (among which miR-133a, miR-34a, and miR-
Figure 5. EpiC-treated CStCs express functionally competent ion channels. In panel (A) a family sodium current recorded from a
representative EpiC-treated TTX (10 mM) low -sensitive CStC, following the application of a standard depolarizing protocol (see inset), is shown. (B)
Mean current-voltage relation of normalized TTX-sensitive currents showing a threshold of activation around 240 mV and a peak around 0 mV. (C)
SCN5A and SCN2A genes were up-regulated (n=3, *P#0.05) by real-time PCR analysis. (D) Western Blot evidences increase of the type V (NaV1.5) and
type II (NaV1.2) voltage-gated sodium channel protein level in CStC cells exposed to EpiC (n=5, *P#0.05). FL=full length protein. (E) In few cells,
membrane hyperpolarization in the range 235 to 2125 mV (see inset) revealed an inward current with the kinetic features of the native pacemaker If
current. (F) Plot of the mean activation curve obtained from the analysis of the If currents recorded in a subset of EpiC-treated CStC.
doi:10.1371/journal.pone.0051694.g005
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vised hierarchical cluster analysis was performed using the whole
dataset of 261 microRNAs, revealing that the global expression
profile well discriminates between the two groups of treatment
(Figure S3). Likewise, unsupervised cluster analysis of the
differentially expressed microRNAs correctly discriminated be-
tween EpiC and control treated CStC, sorting them into two
independent groups (Figure 4). In addition, it showed two clusters
of microRNAs with highly correlated expression, the first
increased and the latter decreased in EpiC-treated cells, which
may be deemed as a specific signature of co-regulated microRNAs.
EpiC Treatment Changes CStC Electrophysiological
Properties
The exposure to EpiC had a profound impact on CStC
function, determining the appearance of electrophysiological
features typical of cells committed towards the cardiomyocyte
lineage. Specifically, a significant fraction (44.8%, 13 out of 29
cells) of EpiC-treated cells exhibited a fast-activating inward
sodium current (Figure 5A), which activated at voltages more
positive than 240 mV, peaked around 0 mV, and was completely
blocked by TTX (10 mM, Figure 5B). At a lower concentration
(50 nM) TTX had variable effects on sodium current. In fact, in a
group of cells, sodium current was not blocked at all (n=3) while
in another group the block ranged from 38 to 94% (mean value:
76.369.2%, n=3, data not shown). These results suggest that
EpiC-treated cells may present both TTX-sensitive and TTX-
resistant sodium currents. Accordingly, expression analyses
showed that, in the presence of EpiC, the type V (NaV1.5) and
type II (NaV1.2) voltage-gated sodium channels (known for having
different TTX sensitivity and encoded by the SCN5A and the
SCN2A genes, respectively) were significantly up-regulated, both
at the mRNA (Figure 5C) and at the protein level (Figure 5D). A
pacemaker If current (Figure 5 E and F) has also been recorded in
5 out of 33 EpiC-treated cells (15.1%), with kinetic properties
compatible with those of immature cardiomyocytes and of native
pacemaker cells (V1/2: 274.465.7 mV, n=3; Figure 5E and F)
[27]. Accordingly, EpiC increased the expression of the pacemaker
channel subunit HCN4 (Figure S4). Notably, CStC maturation
towards the cardiomyocyte lineage was far from being complete,
as demonstrated by the absence of the intracellular Ca2+ handling
proteins NCX1 and RyR2 (not shown) and the depolarized resting
potential characterizing CStC exposed to EpiC (212.762.7 mV,
n=7). This last observation is in accordance with the negligible
expression of the inward rectifying IK1 current (0.4360.04 pA/pF
Figure 6. EpiC treatment modifies CStC epigenetic landscape. Western Blot analysis showing histone modification changes in EpiC-treated
CStC compared to GM. (A) H3 modifications: H3K9Ac, H3K4Me3, H3K27Me3, H3K9Me3, and H3S10P. (B) H4 modifications: H4K16Ac, H4K20Me, and
H4K20Me3. The same filter was probed with anti-total histone H3 or H4, respectively, to control for equal nuclear protein loading. Band densitometric
analyses are reported in the bar graphs on the right (n=3, *P#0.05).
doi:10.1371/journal.pone.0051694.g006
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setting the resting potential of working cardiomyocytes.
EpiC Treatment Modulated CStC Epigenetic Landscape
As expected by the composition of the EpiC described above,
EpiC-treated CStC revealed a significantly lower HDAC Class I
activity compared to cells kept in control condition (Figure S5) and
changes in a number of genome wide histone modifications could
be detected. Specifically, in agreement with its anti-proliferative
effect EpiC also induced a significant decrease in Histone H3
phosphorylation at Ser10 (H3S10P, Fig. 6A) [28]. Further, we
observed a global decrease in histone H3 lysine 9 trimethylation
(H3K9Me3) and H4 lysine 20 trimethylation (H4K20Me3),
paralleled by an increase in histone H4K20 monomethylation
(H4K20Me, Fig. 6A and B). These modifications are compatible
with an open chromatin structure and have been reported in cells
undergoing differentiation or cell cycle arrest [29]. On the other
hand, an increased density of the permissive marks histone H3K4
trimethylation (H3K4Me3) [30] and histone H4K16 acetylation
(H4K16Ac) [31] was observed (Fig. 6 A and B), suggesting the
presence of cells with a high developmental potential [32]. Along
this line of evidence, repressive markers [33] remained stable
(H3K27Me3) or were significantly down-modulated (H3K9Me3
and H4K20Me3), suggesting that EpiC-treated cells underwent a
site-selective chromatin remodelling process leading to regulation
of gene transcription.
EpiC Introduces Chromatin Changes at Specific-gene
Promoters
To validate the hypothesis that Epic may specifically regulate
gene expression, a series of chromatin immunoprecipitation (ChIP)
experiments were performed in CStC cultured in the presence or
the absence of EpiC. Specifically, the highly divergent H3K4Me3
and H3S10P were used to immunoprecipitate chromatin, followed
by real-time PCR to detect the relative modulation of these
specific histone modifications in the promoter region of c-Kit,
MDR-1, Nkx2.5 and nucleostemin. As shown in Figure 7A and B
and in Figure S6A, H3K4Me3 association to c-Kit, MDR-1, and
Nkx2.5 promoter was increased by EpiC treatment, suggesting
that chromatin conformational modifications may account for the
increased expression of these genes (Figure 7C). Accordingly, the
presence of H3K4Me3 and H3S10P in the NKX-2.5 and
nucleostemin (human GNL3 gene product) promoters was
reduced, suggesting local structural changes as the basis of their
down-regulation (Figure S6B).
Discussion
Resident cardiac stem cells are specialized multipotent cells
which, at very low rate, contribute to cardiomyocyte turn-over or
cardiac post-ischemic regeneration. They are present in defined
cardiac districts, identified as niches, in which these cells are kept
quiescent until activation signals come [17]. Specific markers
identify a cardiac stem cell, including the presence of c-Kit and the
P-pump (MDR-1) gene products [16,17]. Adult cardiac stem cells
are neither easily grown ex-vivo nor effectively differentiated into
mature cardiomyocytes. Further, the preparation of near-termi-
nally differentiated cardiomyocytes may not be the best approach
for applications aimed at cardiac regeneration where maximum
plasticity is required to regenerate all the cell types forming
damaged tissues.
Our group has recently isolated, characterized and efficiently
amplified a human population of adult cardiac mesenchymal-like
stromal cells (CStC) showing in vitro and in vivo cardiovascular
plasticity [5]. Although CStC proneness to acquire cardiomyo-
genic markers was higher than that of syngeneic bone marrow
cells, CStC efficiency to differentiate into adult cardiovascular cell
types remained low, in spite of the expression of detectable mRNA
encoding for early cardiovascular markers including c-Kit,
GATA4 and GATA6 [5].
In the present work, CStC differentiation potential was
improved by using a novel combination of small epigenetically
active molecules, defined here as epigenetic cocktail, or ‘‘EpiC’’.
This cocktail was designed to modify the CStC chromatin
landscape and, thus, to unmask and drive CStC plasticity possibly
towards the cardiovascular lineage. In detail, EpiC was made of: (i)
all-trans retinoic acid (ATRA), which has genome-wide regulation
properties [34] and whose receptors are known to recruit p300
and CBP acetyl-transferases facilitating their action at the histone
level of specific gene loci [35]. Relevant for this study, retinoic acid
retains well known morphogenetic properties including a profound
effect on heart development and regeneration [36]; (ii) phenyl
Figure 7. Effects of EpiC treatment on specific-gene promoters.
ChIP experiments, performed on CStC isolated from 2 different patients,
show that H3K4Me3 association to (A) c-Kit and (B) MDR-1 promoter is
enriched after EpiC treatment, while H3S10P is decreased. Data are
expressed as relative enrichment of specific histone modifications i in
EpiC-treated cells compared to GM measured by real-time PCR
amplification. (C) Real-time RT-PCR analysis of c-Kit and MDR-1 mRNA
in EpiC-treated CStC (n=3, *P#0.05 and ****P#0.005).
doi:10.1371/journal.pone.0051694.g007
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inhibitors, which are known to enhance mesoderm maturation
[37]; (iii) diethylenetriamine/nitric oxide (DETA/NO), a nitric
oxide donor associated to cell survival growth arrest in vascular
cells [38] and increased mesendoderm differentiation in mouse ES
cells [10]; (iv) a reduced serum content, known to induce
spontaneous differentiation in a variety of cell types including
C2C12 myoblasts [39] or cardiac mesoangioblasts [40]. Impor-
tantly, all drugs used in this study are approved for clinical use or,
in case of DETA/NO, currently undergoing clinical trials.
The idea that stem cell fate can be modulated by specific
chemicals dates back decades but, recently, an increasing number
of studies are showing the potential role of small molecules to
promote cardiogenesis in mouse ES cells including different BMP
inhibitors such as dorsomorphin [41] and Wnt pathway modu-
lators [42]. On the other hand, similar attempts on adult cells were
inefficient and the induction of true cardyomyogenesis is still
vigorously debated. In 1999 Makino and colleagues described the
appearance of spontaneously beating MHC, MLC-2v, GATA4,
Nkx2.5 positive cells following treatment of immortalized murine
bone marrow stromal cells with 59-azacytidine (5-AZA) [43]. Since
then, this drug was commonly used to induce cardiomyogenesis in
isolated cells [44]. Nevertheless, in some experiments several cells
stained positive for adipogenic markers suggesting that this method
was not cardiac selective, while other groups were unable to
reproduce these findings [45]. Of note, the putative mechanism of
5-AZA induced cardiomyogenesis was firstly attributed to
demethylation of cardiac-related genes. However, a study by
Cho et al. [46] demonstrated that the effect of 5-AZA was not
related to the epigenetic activation of cardio-specific genes, but
rather to the transcriptional inhibition of the glycogen synthase
kinase (GSK)-3 gene, a major player in the Wnt signaling pathway
[46]. In this light, our findings suggest that the EpiC treatment
determines global activation-prone changes in chromatin struc-
ture, including that at c-Kit, MDR-1 and Nkx2.5 promoters.
Importantly, the expression of these genes was induced without
apparently altering that of non-cardiac osteogenic and adipogenic
differentiation markers. This suggests that CStC response to EpiC
may be predominantly cardiovascular oriented [10,47]. In fact,
along with the expression of adult cardiac stem markers, EpiC
treatment also induced the up-regulation of specific transcription
factors associated with the vascular and cardiomyocyte lineage
commitment.
It is widely accepted that microRNAs (miRs), are important for
cardiac gene expression regulation and differentiation control
[48,49]. In the present study, miR expression has been evaluated
by profiling analysis. The evidence that unsupervised cluster
analysis correctly separated between EpiC-treated and control
CStC, further indicates that the EpiC treatment is potentially able
to induce a specific transcriptional programme. Specifically, the
expression of miR-133a, associated with cardiomyogenic differ-
entiation [50], was strongly up-regulated, together with the
expression of miR-210 and mir-34a, involved in stem cell survival
[51] and negative growth control [52], respectively. Of note, miR-
155 whose expression is associated with proliferation [53] and to
the protection of cardiomyocyte precursors from apoptosis [54],
was down-modulated in agreement with the reduced proliferation
ability observed in EpiC-treated CStC. Interestingly, a recent
paper by Anversa and co-workers shows that microRNA typically
associated to adult cardiomyocytes (such as miR-1, mir-499 and
mir-133) are expressed in cardiovascular precursors, but at lower
levels than in adult cardiomyocytes [49]. In this light Epic-treated
CStC expressing miR-133, more closely resemble cardiovascular
precursors than control CStC, in which miR-133 expression is
very low.
Based on the expression of typical stem and cardiovascular
precursor markers and considering previous hypothesis for
cardiovascular stem cell differentiation hierarchy in the adult
heart [16], it is difficult to establish the differentiation stage to
which CStC may belong. The fact that untreated CStC are
GATA4, GATA6 and Mef2C positive, but only EpiC-treated
CStC are cKit, MDR-1and VEGFR2 positive suggests that our
cocktail may induce a cascade of events able to reprogram CStC
towards a more immature state, characterized by the expression of
cardiovascular stem cell markers [55]. On the other hand, EpiC-
treated cells also up-regulated some markers associated with
differentiating cardiomyocyte precursors (i.e. Nkx2.5, Gata4, a–
sarcomeric actin, a–myosin heavy chain, miR-133a) and exhibited
functional, although not yet operational, properties typical of
differentiating cardiomyocytes, suggesting that EpiC treatment
may induce cardiomyogenic differentiation at least in a fraction of
the CStC population. It is thus possible that our approach induced
the production of a mixed population composed of cells at
different stages of differentiation, or acted on different cell
populations present inside the CStC preparations. More experi-
ments are required to elucidate this important point.
Importantly, many cells presented a fast sodium current
(normally responsible for the action potential upstroke), which,
however, was small in size and with kinetic properties slightly
different from those of mature channels. In fact, TTX-sensitivity
and expression analyses evidenced that EpiC-treated cells
expressed both the TTX-resistant NaV1.5 isoform, the primary
cardiac type, and the TTX-sensitiveNaV1.2 isoform, a typical
neuronal type which has been also detected, albeit at low levels, in
the mouse and human hearts [56,57].
Moreover, few cells displayed the If current, which, although
negligible in the adult ventricle, is present in atria and ventricles
during the late embryonic and perinatal stage [27,58].
However, due to the lack of inwardly rectifying potassium
currents, such as IK1, EpiC-treated cells exhibited a depolarized
resting potential keeping both the Na+ and the HCN4 channels
inactive, thus preventing the Epic-treated CStC cells from
acquiring induced or spontaneous electrical activity.
In conclusion, it is reported here the first evidence that CStC
may be chemically reprogrammed to acquire functionally compe-
tent cardiac precursor-like features.
Supporting Information
Figure S1 CStC characterization and Epigenetic Cock-
tail (EpiC) design. (A) Representative FACS analysis of CStC
surface markers. (B) Western blot showing MDR-1, c-Kit, and
VEGFR-2 expression of CStC cultured in growth medium (GM)
or in low serum (LS) with or without epigenetic drugs for 7 days.
ATRA=all-trans-retinoic acid; PB=phenyl butyrate; DETA/
NO=diethylenetriamine/nitric oxide; EpiC=LS+ATRA+PB+-
DETA/NO. (C) Real-Time RT-PCR analysis demonstrates no
up-regulation of adipogenic (Adipsin and PPRc2) and osteogenic
(Osteopontin) markers (n=3). ns=not significant.
(TIF)
Figure S2 Effects of EpiC treatment on c-Kit and MDR-1
expression in CStC. (A) Representative immunofluorescence
images for c-Kit and MDR-1 in GM and EpiC-treated CStC.
Original magnification: 206. (B) Rhodamine 123 assay in GM and
EpiC treatments (n=4). Only EpiC-treated CStC were able to
extrude Rhodamine through Verapamil sensitive MDR-1 channels.
(TIF)
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and EpiC-treated CStC. Unsupervised cluster analysis was
performed using the whole dataset of microRNAs that passed the
quality assurance and filtering criteria: the global expression
profile discriminates treatment groups.
(TIF)
Figure S4 Effect of EpiC treatment on the expression of
the pacemaker channel subunit HCN4 in CStC. Repre-
sentative immunofluorescence images for HCN4 in GM and
EpiC-treated CStC. Original magnification: 406.
(TIF)
Figure S5 Effect of EpiC treatment on HDAC activity in
CStC. Bar graphs show Class I HDAC activity in CStC cultured
in GM or EpiC for 7 days (n=4; * P#0.05).
(TIF)
Figure S6 Effects of EpiC treatment on specific-gene
promoters in CStC. (A) and (B) Bar graphs show relative
enrichment for H3KMe3 and H3S10P in Nkx2.5 and GNL3
(nucleostemin) promoter.
(TIF)
Table S1 List and working concentrations of primary
antibodies used.
(DOC)
Table S2 List of primers for Real-Time RT-PCR.
(DOC)
Table S3 microRNA normalized relative expression
levels in cardiac mesenchymal stromal cells (CStC)
cultured in growth medium (GM) or Epigenetic Cocktail
(EpiC) are expressed as mean ± SD. The dataset includes
microRNAs that passed the quality assurance and filtering criteria.
(DOC)
Document S1 Additional Method section.
(DOC)
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